Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

丹麦制药公司诺和诺德（Novo Nordisk A/S）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Eli Lilly and Company (NYSE: LLY)今天宣布,其用于开始胰岛素治疗的2型糖尿病成年患者的每周一次胰岛素efsitora alfa ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...